APG-279

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameAPG-279
Drug Alias NameAPG-990/APG777APG279
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor ligand superfamily member 4 blockersInterleukin-13 inhibitors
TargetsTumor necrosis factor ligand superfamily member 4Interleukin-13
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[4] 
CombinationsYes APG-990Zumilokibart
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesApogee Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesApogee Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A